New immune cell therapy takes on childhood cancers that Won't quit
NCT ID NCT07172958
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new type of cell therapy for children whose embryonal tumors (rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor) have returned or not responded to standard treatments. The therapy uses the patient's own immune cells, engineered to better recognize and attack cancer cells. The main goal is to find a safe dose and watch for serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
engineered immune cells (B7-H3 CAR T cells and PRAME-targeting T cells)
What this could lead to
If it works, this could point toward a new treatment option for children with hard-to-treat embryonal tumors that have come back or not responded to standard therapy.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not yet on effectiveness. The treatment can cause severe side effects like cytokine release syndrome and nerve toxicity. It may not shrink tumors or help patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WILMS TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's National Hospital
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Childrens National Hospital
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact